3 April 2024
| Zhihang Cheng
|
Retina / Uvea / Vitreous
This review article summarises the current evidence base in the treatment options for diabetic macular oedema (DMO). The authors have included many real-world data studies that provided valuable insights into the optimal management of DMO. The authors argue that these studies, when combined with randomised control trial (RCT) data, provide the most effective evidence-based DMO guidelines. In addition, the authors suggest that real world data will identify low frequency safety signals notably for novel approved drugs. Lastly, the authors draw attention to emerging technologies like AI, big-data or software linkage and how they will increase the utilisation of real-world data.